Effects of the progestagen-only contraceptive implant implanon® on transforming growth factor β1 and endothelin-1

Hormone and Metabolic Research

Volumn 40, Issue 10, 2008, Pages 692-696

  Merki Feld, G S ^a   Imthurn, B ^a   Seifert, B ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Atherogenesis; Cardiovascular risk; Contraception; Endothelin 1; Implanon ; Progestagen only pill; Transforming growth factor

Indexed keywords

CONTRACEPTIVE AGENT; ENDOTHELIN 1; ETONOGESTREL; GESTAGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; ATHEROGENESIS; CONTRACEPTION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; PREGNANCY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVE AGENTS, FEMALE; DEMOGRAPHY; DESOGESTREL; ENDOTHELIN-1; FEMALE; HUMANS; LIPIDS; PROGESTINS; PROSTHESES AND IMPLANTS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 54049091964     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1073149     Document Type: Article

References (39)

1. Feinberg MW, Watanabe M, Lebedeva MA, Depina AS, Hanai J, Mammoto T, Frederick JP et al. Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem 2004; 279: 16388-16393
2. Miller AP, Chen YF, Xing D, Feng W, Oparil S. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 2003; 42: 657-663
3. The ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006; 12: 483-497
4. Merki-Feld GS. Cardiovascular risks associated with low-dose combined oral contraceptives. Ther Umsch 2001; 58: 564-569
5. Merki-Feld GS, Imthurn B, Keller PJ. The effect of the menstrual cycle and of ethinylestradiol on nitric oxide, endothelin-1 and homocysteine plasma levels. Horm Metab Res 2000; 32: 288-293
6. Merki-Feld GS, Imthurn B, Keller PJ. Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. Metabolism 2002; 51: 1216-1221
7. Doring A, Frohlich M, Lowel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004; 172: 281-286
8. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4: 67-73
9. Ghosh J, Murphy MO, Turner N, Khwaja N, Halka A, Kielty CM, Walker MG. The role of transforming growth factor beta1 in the vascular system. Cardiovasc Pathol 2005; 14: 28-36
10. Cipollone F, Fazia M, Mincione G, Iezzi A, Pini B, Cuccurullo C, Ucchino S et al. Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke 2004; 35: 2253-2257
11. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399-404
12. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440
13. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238: 249-252
14. Gonzalez W, Chen Z, Damon DH. Transforming growth factor-beta regulation of endothelin expression in rat vascular cell and organ cultures. J Cardiovasc Pharmacol 2001; 37: 219-226
15. Rodriguez-Vita Jr OM, Ruperez M, Esteban V, Sanchez-Lopez E, Plaza JJ, Egido J. Endothelin-1, via ETA-receptor and independently of transfroming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 2005; 22: 125-134
16. Fakhouri F, Placiers, Ardaillou R, Dussaule JC, Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol 2001; 12: 2701-2710
17. Merki-Feld GS, Keller PJ. Decrease in endothelin-1 plasma levels during the menstrual cycle and after ethinylestradiol treatment. Ann Intern Med 1999; 131: 394
18. Djurovic S, Os I, Hofstad AE, Abdelnoor M, Westheim A, Berg K. Increased plasma concentrations of TGF-beta1 after hormone replacement therapy. J Intern Med 2000; 247: 279-285
19. Makarainen L, Beek A van, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon® compared with Norplant. Fertil Steril 1998; 69: 714-721
20. Biswas A, Viegas OA, Roy AC. Effect of Implanon® and Norplant subdermal contraceptive implants on serum lipids: a randomized comparative study. Contraception 2003; 68: 189-193
21. Baal WM Van, Emeis JJ, Kenemans P, Kessel H, Peters-Muller ER, Schalkwijk CG, Mooren MJ van der et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999; 29: 913-921
22. Silvestri A, Gambacciani M, Vitale C, Monteleone P, Ciaponi M, Fini M, Genazzani AR et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005; 50: 305-311
23. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, Kuhl H. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 2003; 67: 361-366
24. Polderman KH, Stehouwer CD, Kamp GJ van, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-432
25. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, Daemen MJ. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-982
26. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1995; 1: 74-79
27. Tashiro H, Shimokawa H, Sadamatu K, Yamamoto K. Prognostic significance of plasma concentrations of transforming growth factor-beta in patients with coronary artery disease. Coron Artery Dis 2002; 13: 139-143
28. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med 1995; 1: 932-937
29. Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, Tsushima H et al. Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992; 83: 676-679
30. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005; 52: 111-118
31. Fraccarollo D, Galuppo P, Bauersachs J, Ertl G. Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res 2002; 54: 559-567
32. Fukuda G, Khan ZA, Barbin YP, Farhangkhoee H, Tilton RG, Chakrabarti S. Endothelin-mediated remodeling in aortas of diabetic rats. Diabetes Metab Res Rev 2005; 21: 367-375
33. Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, Grainger DJ. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996; 271: 31367-31371
34. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460-462
35. O'Neil CH, Boffa MB, Hancock MA, Pickering JG, Koschinsky ML. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem 2004; 279: 55187-55195
36. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-1658
37. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing eithet desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 2001; 64: 295-299
38. Macy PA. Homocysteine: predictor of thrombotic disease. Clin Lab Sci 2001; 14: 272-275
39. Bennink HJ. The pharmacokinetics and pharmacodynamics of Implanon®, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5 (Suppl 2): 12-20